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ABSTRACT 
The enzyme which forms glucocerebroside, ceramide:Ul)P-glucose glucosyltransferase, is inacti- 
vated in vitro by a cationic analog of cerebroside, 2-decanoylamino-3-morpholinopropiophenone. A 
study of the inhibitor using intraperitoneal injection into young mice showed that the level of the 
enzyme activity in liver was appreciably lowered between 3 and 6 hr after injection. The activity in- 
creased subsequently, overshooting the normal level within 24 hr by about 20%, then returning to 
normal within the next 24 hr. Additional effects observed in liver were an increase in lipid content 
(primarily in the triglyceride fraction and ceramides) and a decrease in the glucocerebroside level. 
Body temperature dropped rapidly. Markedly similar effects were produced by injecting chlorproma- 
zinc, which was tried in order to reduce the hyperirritability and inhibitory effects on monoamine 
oxidase previously demonstrated by the glucosyltransferase inhibitor. Chlorpromazine did indeed 
block the hyperirritability and resulted in enhancement of the keto amine's effects on the enzyme and 
lipids. It is possible that the two drugs in combination would be helpful in ameliorating the symptoms 
due to the cerebroside accumulation that occurs in Gaucher disease. Diazepam also produced a re- 
duced level of glucosyltransferase. A color reaction for chlorpromazine, possibly suitable for quantita- 
tive determination in tissues, was accidentally discovered. 
Lipids 17:538-543, 1982. 
Glucocerebroside (glucosyl ceramide)  is 
synthesized f rom ceramide and UDP-glucose 
by a glucosyltransferase,  EC 2.4.1.80 (1,2). 
It is also hydro lyzed  by a glucosidase to cera- 
mide and glucose (3). In the human  genetic 
disorder Gaucher  disease, the glucosidase is 
ineff ic ient  and glucocerebroside accumulates  
to a great extent .  If  the manifold  s y m p t o m s  
of the disorder are due primarily to the accum-  
ulat ion of  the lipid, it may be possible to 
ameliorate  the symptoms  by adminis t ra t ion 
of  a drug that  inhibits the synthesis of  the  lipid. 
Hopeful ly ,  af ter  an initial period o f  deple t ion ,  
the rate o f  synthesis can be matched  to the 
individual 's  rate of  hydrolysis .  This labora tory  
has described several such inhibitors which 
work in vitro (4,5) and we now describe some  
of the effects  p roduced  by one of  the com- 
pounds in young  mice.  The inhibi tor  used here,  
DMP, is an analog o f  the e n z y m e  produc t  gluco- 
cerebroside.  The phenyl  group in the inh ib i to r  
resembles the long aliphatic chain o f  sphingo- 
sine, the decanoylamino  group resembles the 
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much longer  fa t ty  acid amide found in the 
natural ly occurr ing lipid, the ke tone  group 
resembles the 3-OH of  sphingosine,  and the 
morphol ine  resembles the glucose moie ty .  
Because the ke tone  group has a beta  relat ion- 
ship to the morphol ine  ni t rogen a tom,  DMP is 
chemical ly reactive and it is likely that  it in- 
activates the glucosyltransferase by direct,  
covalent  react ion with the active site. 
M A T E R I A L S  A N D  M E T H O D S  
Ceramide:UDP-glucose glucosyltransferase 
was assayed by a 2-phase l iquid scinti l lation 
me thod ,  in which 5 or  6 mg of  homogen ized  
liver was incubated in a plastic count ing  vial 
with oc tanoyl  sphingosine as the glucose 
accep te r  (6,7). 
Male ICR mice (Harlan Industries,  Indianap- 
olis, IN), 24 days old, were mainta ined for 6 
days in our  animal room on mouse  chow in 
wi re -bo t tomed cages and 12 h r  l ight /dark 
cycles. They were divided in to  groups of  6-10, 
matched  in average weight  and weight  distribu- 
t ion,  and injected in t raper i toneal ly  (ip) with 
0.2 ml of  saline or  0.2 ml o f  saline conta ining 
CPZ-HCI (10 mg/kg  body wt).  Af te r  1 hr,  hal f  
the mice were injected with 0.2 ml saline and 
the o ther  half  were injected with 0.2 or  0.4 ml 
of  DMP~ (250 or  500 mg/kg) ,  freshly dis- 
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solved in saline. Thus, each mouse received 2 
injections (e.g., the controls received 2 saline 
injections 1 hr apart, the CPZ-DMP mice re- 
ceived CPZ first, then DMP 1 hr later). At a 
later point, the livers were removed, washed 
with cold saline, wiped dry, weighed, cooled on 
Dry Ice, and stored at -70 C in groups of 3, 4 
or 5. 
For enzyme assays, the pooled livers were 
homogenized in water. For lipid analyses, they 
were homogenized with hexanc/isopropanol 
3:2 (8) and processed as described separately 
(9,10). Total lipids were determined gravi- 
metrically with the extract from 0.4 g l iver ,  
washed with conc aq Na sulfate to remove non- 
lipids ( 11 ). 
RESULTS 
The initial studies with DMP were carried 
out with mice from Spartan Research and only 
the glucosyltransferase activities in liver were 
measured. Injection of DMP (250 mg/kg) pro- 
duced distinct decreases in the enzyme activi- 
ties, with a maximal decrease in the specific 
activities of about 48% in 2-6 hr. Sacrifice at 
later time-points showed smaller reductions, 
evidently due to loss of the inhibitor and, 
probably, to resynthesis of the enzyme. How- 
ever, by 24 hr after the injection, the enzyme 
specific activity had risen to 20% above normal. 
It was back to normal after a second day. 
It was noticed that,  shortly after injection, 
the mice exhibited symptoms of hyperirritabil- 
ity, body tremors and head twitching, as well as 
abduction of the hind legs. They appeared to be 
normal after a period of about 3 hr. Tests of 
DMP in vitro and after injection showed (12) 
that it possesses the ability to inhibit mono- 
amine oxidases, apparently by a covalent in- 
activation similar to that seen with the glucosyl- 
transferase. To reduce the symptoms of central 
nervous system stimulation, and to enable us to 
administer higher doses of DMP, we tried inject- 
ing CPZ 1 hr before the DMP. The CPZ did 
indeed eliminate the hyperactivation effect of 
DMP without affecting the recovery period (3 
hr). The unexpected finding (Table 1 ) w a s  
made that CPZ (10 mg/kg) was as effective as 
DMP (250 mg/kg) in lowering the level of 
glucosyltransferase, even showing the same 
rebound phenomenon at 25 hr. Particularly 
satisfying was the observation that the two 
drugs produced additive effects. 
Tests with sedating drugs, using mice killed 3 
hr after injection, showed 0.997 nmol/hr of 
cerebroside synthesized by 6 mg of liver from 
control mice, a 25% decrease with CPZ, a 10% 
decrease with reserpine (2.5 mg/kg), and a 14% 
decrease with diazepam (10 mg/kg). Stimulat- 
ing drugs (8 mg/kg D-amphetamine, 8 mg/kg 
metrazol) had no effect. 
The Spartan mice became unavailable, so we 
tested several strains of mice for their enzyme 
levels and reaction to DMP. It was found that 
none of the strains tested had as high a specific 
activity as the Spartan mice, nor was the vari- 
ability between mice lower, even with inbred 
mice (C3H). The observed specific activities 
for cerebroside synthesis by 5 mg of liver were 
443 -+ 50 pmol with Charles River CD-1 out- 
bred albinos, 490 + 70 pmol with Charles River 
C3H mice, 691 -+ 50 pmol with Charles River 
CF-1 mice, and 496 + 60 pmol with ICR mice. 
Although the ICR mice did not have the highest 
specific activity, they responded a little better 
to DMP and were used for further tests. 
Trials of various doses of DMP with these 
mice, without CPZ, showed that they appeared 
normal within 3 hr after injection of 500 
T A B L E  1 
Ef fec t  o f  C h l o r p r o m a z i n e  a n d  D e c a n o y l a m i n o m o r p h o l i n o p r o p i o p h e n o n e  
o n  Liver  G l u c o s y l t r a n s f e r a s e  o f  S p a r t a n  Mice 
Drug  i n j e c t e d  
C o n t r o l s  CPZ DMP CPZ + D M P  
2-hr  g r o u p s :  a 
C e r e b r o s i d e  f o r m e d  ( n m o l ] 6  mg)  0 .91  0 . 4 9  0 . 4 8  0 . 3 0  
I n h i b i t i o n  (% b e l o w  c o n t r o l s )  - 4 7  4 8  67  
24 -h r  g r o u p s :  a 
Cerebroside f o r m e d  ( n m o l / 6  rag)  0 . 7 5  0 . 8 8  0 . 9 0  1 .06 
Inc rease  (% a b o v e  c o n t r o l s )  -- 18 19 41  
a T i m e s  s h o w n  are  f o r  an ima l s  i n j e c t e d  w i th  DMP.  All an ima l s  w e r e  i n j e c t e d  1 h r  p re -  
v ious ly  w i th  sa l ine  o r  CPZ.  Values  s h o w n  are averages  o f  2 va lues  obtained by p o o l i n g  2 
g r o u p s  o f  3 l ivers (i .e. ,  6 m i c e ] g r o u p )  a n d  a s s a y i n g  fo r  g l u c o c e r e b r o s i d e  s y n t h e t a s e .  
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mg/kg; at 750 mg/kg, recovery took 6 hr and, 
at 1 g/kg, they recovered within 24 hr. All mice 
seemed quite normal for the next 3 wk. 
Trials with trifluoperazine, a drug related to 
CPZ but more potent as an antipsycliotic, 
showed only a 7% decrease in glucosyltransfer- 
ase at 10 mg/kg and the additive effect with 
DMP was slight. Haloperidol, an antipsychotic 
drug resembling DMP in structure, produced 
little or no decrease 3 hr after injecting 5 
mg/kg. 
An experiment with CPZ and DMP was 
carried out with the ICR mice, which were 
sacrificed 2 hr after DMP injection at a dosage 
of 500 mg/kg (sacrificed 3 hr after CPZ injec- 
tion). The reduction in glucosyltransferase was 
not  as large as with Spartan mice, but the two 
drug effects were still additive (Table 2). The 
body weights were unaffected in this short 
period of exposure to the drugs, whereas the 
liver became distinctly enlarged in all three 
drug-treated groups. However, there was no sign 
of additivity here. 
The effects of CPZ and DMP on glucosyl- 
transferase were found also with female ICR 
mice, possibly to a greater degree than in males. 
The depression in enzyme activity (about 42% 
for DMP and DMP+CPZ) appeared within about 
3 hr and persisted about 3 hr, then the over- 
shoot effect (about 41%) was visible 23 hr after 
the initial injection. 
Another trial in which the drugs were 
allowed to act for 5 hr (for DMP) showed that 
CPZ could produce a marked increase in liver 
weight, but here the effect of DMP seemed to 
be absent (Table 3). Determination of the total 
VUNNAM AND N.S. RADIN 
lipids in the livers showed that part of the 
weight increase was due to an increase in the 
weight of the lipids. The ceramide concentra- 
tions also increased, more so than the total 
lipids, but the cerebroside level decreased. All 
the lipid changes, like the cerebroside syn- 
thetase changes, showed additivity between the 
two drugs. It was evident that the changes in 
cerebroside levels showed a parallelism with 
the drug-induced reduction in glucosyltransfer- 
ase. The relatively large loss of cerebroside, up 
to 32%, in just 5-6 hr shows that this lipid 
undergoes a relatively rapid turnover. 
A shorter term study, in which the DMP was 
allowed to act only 2 hr (Table 4), showed 
similar, but smaller, changes in ceramide and 
cerebroside concentrations. 
A semiquantitative examination of the liver 
lipids by thin layer chromatography (TLC), 
with visual evaluation of the charred spots, 
revealed that the increased level in liver lipids 
was due almost entirely to an increase in trigly- 
ceride level. Evidently, the two drugs stimulate 
a very rapid biosynthesis of triglyceride or 
mobilization from the body to the liver. (How- 
ever, the solvent that was used for chromatog- 
raphy could not discriminate between triglycer- 
ide and dialkyl acyl glycerol, an appreciable 
component of normal liver.) 
It was also noticed, during handling of the 
mice, that the two drugs produced a marked 
lowering of body temperature in the mice. 
CPZ has previously been noted to weaken 
the body's ability to control its temperature, 
in animals and in human patients (13), and 
t h e  toxicity of the drug depends on the ambi- 
TABLE 2 
Glucosyltransferase in Livers of  ICR Mice after Injection o f  Chlorpromazine 
or Decanoy laminomorph  o l inopropiophenone  
Body wt Liver wt Cerebroside formed Inhibition 
(g) (g) (pm ol /5  rag) (%) 
26.1 1.07 591 
Controls 25.9 (26.1) 1.08 (1.09) 506 (540) - 
26 .4  1.12 523 
25.4 1.27 514 
CPZ-injected 26.9 (26 .1)  1.40 (1 .33)  328 (412) 24 
26.1 1.33 395 
25.3 1.23 506 
DMP-injected 26.2 (26.1) 1.28 (1.21) 372 (398) 26 
26.8 1.11 316 
25.1 1.15 289 
CPZ + DMP 26.5 (26.0) 1.23 (1.21) 251 (263) 51 
26.3 1.24 249 
Values shown are averages from 3 mice, 2 hr after injection of DMP (3 hr after injection 
of CPZ). Values in parentheses are the averages of  the 3 measurements. 
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Liver  L ip ids  a f t e r  I n j e c t i o n  o f  C h l o r p r o m a z i n e  a n d  D e c a n o y l a m i n o m o r p h o l i n o p r o p i o p h e n o n e  
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C e r a m i d e  level C e r e b r o s i d e  level 
B o d y  w t  Liver w t  L ip ids  L ip id  i nc rease  
(g) (g) ( m g / g )  (%) #g /g  Inc rease  #g /g  Decrease  
22 .2  1 .03 51 .3  103  3 8  
C o n t r o l s  22 .3  1 .06  4 8 . 8  -- 105  - 37  - 
140  35 C P Z - i n j e c t e d  22 .6  1 .19 59 .8  1 7  2 5 %  6 %  
22 .3  1 .17  57 .3  120  36  
DM P- in jec ted  22 .4  1 .05 58 .5  15 194  6 9 %  31 2 0 %  
22 .4  1 .03 56 .3  159  30  
192  26  CPZ + DMP- in jec ted  22 .7  1 .18  80 .5  53 72% 3 2 %  
9 22 .4  1 .15 72 .5  167  25  
Values  s h o w n  are averages  f r o m  5 mice ,  i n j e c t e d  5 h r  p r i o r  to  sac r i f i ce  w i t h  D M P  (or  6 h r  w i t h  CPZ) .  
T A B L E  4 
C e r a m i d e  a n d  C e r e b r o s i d e  Levels in t he  Livers o f  C o n t r o l  a n d  T r e a t e d  G r o u p s  o f  ICR Mice 
C e r a m i d e  level b C e r e b r o s i d e  level b 
Liver  w t  a 
(g) #g /g  Inc rease  #g /g  Decrease  
150  3 3  
C o n t r o l s  1 .09  117  - 33  - 
101 32  
154  33  
C P Z - i n j e c t e d  1 .33  132  2 0 %  27 8% 
155 22  
171 33 
DMP- in jec t ed  1.21 2 0 3  4 6 %  2 9  7% 
1 6 4  2 9  
196  2 9  
CPZ + I)MP 1.21 2 0 3  54% 24  2 1 %  
167  24  
aLiver  we igh t s  are the  averages  f r o m  9 mice .  
bVa lues  s h o w n  are  the  averages  f r o m  g r o u p s  o f  3 mice .  All we re  sac r i f i ced  2 h r  a f t e r  
i n j ec t i ng  DMP (3 hr  a f t e r  CPZ) .  
ent temperature (14). Measurements of rectal 
temperature in the mice (Fig. 1) revealed that 
both drugs induced hypothermia in 30 min or 
less and that it persisted for at least 5 hr. Here 
the additive effect of the two drugs was ap- 
parent only during the first 90 min. 
The CPZ effect on glucosyltransferase, un- 
like that produced by DMP, could not be 
demonstrated in incubations with liver homog- 
enate, even at a concentration of 0.3 mM. Thus, 
it is possible that the enzyme is inhibited by 
one or more of the several known metabolites 
of CPZ. Mixing the liver homogenates from 
control and CPZ-injected mice gave only the 
expected intermediate values, indicating an 
absence of soluble inhibitors in the CPZ- 
injected mice. This might mean that a CPZ 
metabolite had combined irreversibly with 
some of the glucosyltransferase, and the 
amount of the free metabolite was too low to 
affect the added normal enzyme. 
An interesting side-observation was the find- 
ing that CPZ could be seen in the liver extracts 
after TLC of the cerebroside fraction (using 
silica gel with chloroform/methanol/water  
24:7:1). The CPZ was visible just above the 
cerebroside pair of bands as a pink spot im- 
mediately after spraying with cupric acetate 
and aq phosphoric acid (15). The color deep- 
ened upon heating, instead of charring to the 
usual gray band. Two /ag or less of CPZ could 
be seen readily and it is possible that the 
LIPIDS,  V O L .  17,  N O .  8 ( 1 9 8 2 )  
542 A . V .  H O S P A T T A N K A R ,  R . R .  V U N N A M  A N D  N.S .  R A D I N  










~ ~c~  CPZ+DMP 
I I I I 1 
I 2 3 4 5 6 
HOURS AFTER INJECTION 
FIG. 1. Rectal temperatures of mice injected with 
chlorpromazine or decanoylaminomorpholinopropio- 
phenone, or both. Data points are averages from three 
mice. 
method-which seems to show no interference 
at a l l -could be useful for quantitative analysis 
of tissues or blood. A similar color reaction 
between CPZ and phosphoric acid has been 
reported for paper chromatograms (16). 
DISCUSSION 
The ability of DMP to lower liver cerebro- 
side concentration, through its known effect 
on ceramide:UDP-glucose glucosyltransferase, 
is encouraging for our goal of treating Gaucher 
disease by chemotherapy. The current approach 
to treatment, injection of normal cerebroside 
glucosidase obtained at great cost from human 
placentas, has not proved effective in reversing 
the progress of the disorder (17). Although 
the interference with regulation of body tem- 
perature by DMP and CPZ is a drawback, this 
problem is readily handled by CPZ-consuming 
patients by the use of appropriate clothing and 
control of body activity. 
The effects of DMP and CPZ in mice on 
glucosyltransferase and cerebroside could be 
attributed to some indirect effect of body 
cooling, but this explanation is improbable 
because the additivity of the drugs in their 
biochemical effects is not paralleled by their 
nonadditivity in reduction of body tempera- 
ture. 
Remarkably many effects on enzyme reac- 
tions and physiological phenomena have been 
demonstrated for CPZ and we can now add 
the observed reduction in glucosyltransferase 
and cerebroside, and the accumulation of 
ceramide. The accumulation of fat in fiver has 
been previously noted in rats (18) and in 
patients (19) given CPZ chronically. However, 
ours seems to be the first demonstration that 
this accumulation appears very quickly, after 
a single dose of the drug. Experiments with 
rats given two single (but heavy) does of CPZ 
have shown a 41% increase in total phospho- 
lipid weight in the liver microsomes within 48 
hr after the initial dose (20). Since CPZ is being 
given to patients over a relatively long period of 
time, sometimes at dosage levels as high as ours, 
one might ask whether there is any effect in 
these patients on sphingolipid metabolism. 
The accumulation of ceramide, seen with 
both drugs, is presumably due to reduction in 
its rate of utilization for glucocerebroside syn- 
thesis without an accompanying decrement in 
its rates of synthesis or hydrolysis. This kind of 
accumulation is seen in the human genetic 
disorder ceramidosis or Farber's lipogranulo- 
matosis, where the defect is in the rate of 
hydrolysis. The second major synthetic conver- 
sion route for liver ceramide is the reaction 
with lecithin to form sphingomyelin (21), but 
this reaction appears to be much slower than 
ceramide glucosylation, at least in vitro. The 
rapid rise in ceramide level suggests that it has 
a relatively high turnover rate in liver. Alterna- 
tively, one could postulate a rapid mobilization 
from the peripheral organs, like triglycerides. 
Ceramides and triglycerides do resemble one 
another in their low polarity and in their deriva- 
tion from fatty acids. 
The overshoot effect observed 24 hr after 
administering the two drugs is not unknown 
with other inhibitors and is presumably the 
result of imprecise regulation of enzyme levels-  
in this case, a temporary overrapid synthesis 
of glucosyltransferase. This lability in the 
enzyme level suggests that it has a high turnover 
rate and is relatively responsive to exogenous 
influences. This interpretation is consistent 
with the results of experiments on the effects 
of protein synthesis inhibitors on the enzyme 
(22). 
It is possible that the large reduction in glu- 
cosyltransferase we produced would not be 
necessary in treating Gaucher disease since the 
accumulation of cerebroside is relatively slow 
and it might suffice to produce only a small 
decrement in its rate of synthesis. In general, 
it seems that organisms possess somewhat more 
hydrolase than the corresponding synthetase; 
that is, there is surplus hydrolase activity. The 
large reduction in cerebroside glucosidase seen 
in Gaucher disease probably does not signify 
so large a decrease in the actual rate of cerebro- 
side breakdown. 
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